ImmunoGen Inc

ImmunoGen — Technical Presentation (September 2019)

24 slides from ImmunoGen's technical presentation, Sep 30, 2019

  1. Slide 1: FORWARD I: Full Data and Exploratory Analyses

    Exhibit 99.3 FORWARD I: Full Data and Exploratory 30 September 2019 Analyses 1 CONFIDENTIAL

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements regarding ImmunoGen’s expectations related to: the design and potential success of ImmunoGen’s future mirvetuximab soravtansine studies and regulatory pathway, including the timing of initiating and receiving data from,

  3. Slide 3: Agenda

    Agenda 1 Overview 2 FORWARD I 3 Closing Remarks 4 Q&A with Dr. Kathleen Moore 3 CONFIDENTIAL

  4. Slide 4: Ovarian Cancer Landscape

    Ovarian Cancer Landscape PLATINUM - SENSITIVE SURGERY DISEASE PROGRESSION MORE THAN 6 MONTHS AFTER PLATINUM TREATMENT PLATINUM – BASED CHEMOTHERAPY +/ - MAINTENANCE MOST DEVELOP PATIENTSPLATINUM-RESISTANT DISEASE LIMITED OPTIONS WITH POOR OUTCOMES DIAGNOSIS ~2 2,000 WOMEN DIAGNOSED ANNUALLY1 PLATINU

  5. Slide 5: Mirvetuximab Soravtansine

    Mirvetuximab Soravtansine KEY ATTRIBUTES • • Distinct target and mechanism of action Demonstrated activity in platinum-resistant and platinum-sensitive disease Well tolerated with differentiated safety profile Potential in other FRα-positive solid tumors DISPLACING CHEMOTHERAPY TO DELIVER MORE GOOD

  6. Slide 6: First Indication and Ongoing Expansion Studies Will Cover Significant Percentage of Recurrent Ovarian Cancer Patients

    First Indication and Ongoing Expansion Studies Will Cover Significant Percentage of Recurrent Ovarian Cancer Patients 2L EXPANDED INDICATIONS ~ 8,000 PATIENTS FRα HIGH 3L 2L FIRST INDICATION ~ 5,000 PATIENTS FRα HIGH 3L 4L * Numbers represent drug treatable US patients. 6 Sources: Decision Resources

  7. Slide 7: Mirvetuximab: Monotherapy Summary and Next Steps

    Mirvetuximab: Monotherapy Summary and Next Steps patient selection and significantly positive outcome FRα expression than intended the end of 2019 outcomes correlated with 7 CONFIDENTIAL Registration Study •Data from FORWARD I inform improve the likelihood of a •New Phase 3 trial in FRα high patient

  8. Slide 8: FORWARD I

    FORWARD I Anna Berkenblit Senior Vice President and Chief Medical Officer 8 CONFIDENTIAL

  9. Slide 9: FORWARD I: Study Design

    FORWARD I: STUDY DESIGN 6 mg/kg (adjusted ideal body weight) once every 3 weeks 2:1 Randomization Stratification Factors: FRα expression (medium or high) Prior therapies (1 and 2, or 3) Choice of chemotherapy Chemotherapy • α=0.05 (two-sided), Power = 90%, Paclitaxel: 80 mg/m2 weekly PLD: 40 mg/m2 o

  10. Slide 10: Baseline Characteristics

    Baseline Characteristics DISEASE CHARACTERISTICS STRATIFICATION FACTORS IC Chemo soravtansine Ovarian 83% 89% Medium 42% 42% Primary Peritoneal 11% 7% No. Prior Lines High Grade Serous 99% 97% 3 35% 35% ECOG Paclitaxel 32% 31% 1 43% 48% Topotecan 23% 23% Bevacizumab 49% 47% Any BRCA Mutation Platinu

  11. Slide 11: Safety Summary

    Safety Summary Deaths on study drug or within 30 days of last dose 4% 6% Dose delays due to related TEAEs 29% 28% 11 *Five and niCneOpNatiFenIDtsEraNndTomIAizLed into the mirvetuximab soravtansine and chemotherapy arms, respectively, did not receive any allocated intervention and were not included i

  12. Slide 12: Most Common Treatment-Related Adverse Events (>20%)

    (>20%): Most Common Treatment-Related Adverse Events Differentiated Safety Profile Grade All 3+ • • • • Mirvetuximab Chemotherapy 56 48 48 46 44 42 40 34 34 33 31 30 28 27 25 26 22 19 15 13 11 9 8 <-;'q-1' q9"-,O<f' Alopecia 7 •<;' q'>vq9"-,O<f' 0 . 0 6 4 4 -2 0 0 0 0 q'>"q9"-,O<f' <;' q'>vqS' "-,O<

  13. Slide 13: Primary Endpoint: Progression-Free Survival (By BIRC)

    Primary Endpoint: Progression-Free Survival (By BIRC) ITT POPULATION FRα HIGH POPULATION 13 *Not signiCficOanNt pFeIrDHEocNhbTerIgApLrocedure HR: 0.981, p value: 0.897 mPFS: 4.1 vs 4.4 months HR: 0.693, p value: 0.049* mPFS: 4.8 vs 3.3 months FORWARD I DID NOT MEET PRIMARY ENDPOINT immunogen

  14. Slide 14: Efficacy Results

    Efficacy Results ITT POPULATION FRα HIGH POPULATION ORR by BIRC 95% CIs 22% vs 12% (17%, 28%) vs (7%, 19%) 0.015 OS (August 2019) (mo.) HR: 0.846 (0.625, 1.145) mOS: 15.6 vs 13.9 0.278 *Nominal p-value ^Not significant based on Hochberg Procedure †≥15-poin improvement in the EORTC QLQ-OV28 Abdominal

  15. Slide 15: FRα Scoring in the Mirvetuximab Soravtansine Program

    FRα Scoring in the Mirvetuximab Soravtansine Program PS2+ SCORING • In all prior studies, PS2+ scoring was used to assess FRα expression • Eligibility determined by scoring intensity and percentage of tumor cells staining at 0, 1+, 2+, or 3+ 10X SCORING • In FORWARD I, a simplified scoring method to

  16. Slide 16: FORWARD I 10X Scoring Compared with Exploratory PS2+ Scoring

    FORWARD I 10X Scoring Scoring (n=333) Compared with Exploratory PS2+ 10X SCORING PS2+ SCORING FRα expression below intended inclusion cutoff Rescoring of the FORWARD I samples using PS2+ indicates: • 34% of patients enrolled in FORWARD I had low FRα levels that should have precluded enrollment; and

  17. Slide 17: PS2+ Rescore: PFS Outcomes and Trends Across Subgroups

    PS2+ Rescore: PFS Outcomes and Trends Across Subgroups PFS HAZARD RATIO PLOT PFS (by BIRC) FRα HIGH mPFS: 5.6 vs 3.2 months *Nominal Cp vOalNueFs IDENTIAL 17 P values from unstratified log-rank test * Mirvetuximab better IC Chemo better HR: 0.549 (95% CI 0.336, 0.897) STRONG TREATMENT EFFECT ININTEN

  18. Slide 18: PS2+ Rescore: Overall Survival in FRα High

    PS2+ Rescore: Overall Survival in FRα High (n=116) (August 2019) 18 CONFIDENTIAL HR: 0.678 (95% CI 0.410, 1.119) mOS: 16.4 vs 11.4 months

  19. Slide 19: PS2+ Rescore: Trends Across Subgroups

    PS2+ Rescore: Trends Across Subgroups 19 CONFIDENTIAL EndpointFRα < 50% (n=114)FRα Medium (n=103) (Mirv vs IC Chemo)(Mirv vs IC Chemo) FRα High (n=116) (Mirv vs IC Chemo) PFS by BIRCHR: 1.458 (0.878, 2.420)HR: 1.015 (0.611, 1.687) (mo.)mPFS: 3.8 vs 5.5mPFS: 4.3 vs 5.6 HR: 0.549 (0.336, 0.897) mPFS:

  20. Slide 20: FORWARD I Conclusions

    FORWARD I Conclusions • • FORWARD I did not meet the PFS primary endpoint in the ITT or FRα high populations In the FRα high population (by 10X scoring), consistent efficacy signals were observed with mirvetuximab soravtansine Mirvetuximab soravtansine was well tolerated with a differentiated safety

  21. Slide 21: MIRASOL Study Design: Phase 3 Registration Trial

    MIRASOL Study Design: Phase 3 Registration Trial for Mirvetuximab Soravtansine Using PS2+ Scoring in FRα High Patients 6 mg/kg (adjusted ideal body weight) once every 3 weeks 1:1 Randomization STRATIFICATION FACTORS IC Chemotherapy Choice (Paclitaxel, PLD, Topotecan) Prior therapies (1 vs 2 vs 3) Pa

  22. Slide 22: Closing Remarks

    Closing Remarks Mark Enyedy President and CEO 22 CONFIDENTIAL

  23. Slide 23: Summary

    Summary patient selection and significantly positive outcome FRα expression than intended the end of 2019 outcomes correlated with 23 CONFIDENTIAL Registration Study •Data from FORWARD I inform improve the likelihood of a •New Phase 3 trial in FRα high patients expected to begin by Exploratory Analy

  24. Slide 24: Q&A

    Q&A 24 CONFIDENTIAL

ImmunoGen — Technical Presentation (September 2019) on 6ix